Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Thirty-six consecutive patients with advanced recurrent Hodgkin's disease resistant to chemotherapy with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) were treated with doxorubicin (Adriamycin), bleomycin, (dacarbazine) DTIC, (lomustine) CCNU, and prednisone (ABDIC). Among the 34 patients evaluable for response, complete remission occurred in 35% and partial remission in 35%. The achievement of complete remission during primary MOPP induction was a statistically significant prognostic factor that predicted complete remission with ABDIC (p less than 0.01). The median time to complete remission was 2 months (range 1-11 mo). The median relapse-free survival time for complete responders is 47 months, and an estimated 53% of all patients who achieve complete remission are projected to be alive, free of disease off therapy at 3 years from initiation of ABDIC. The median survival of all patients is 24 months. The median survival of complete responders, partial responders, and nonresponders is 70, 17, and 4 months, respectively. The survival curve for complete responders is significantly different from that for partial responders (p less than 0.01); the survival curve for partial responders is also significantly different from that of nonresponders (p less than 0.01). Toxicity of ABDIC was acceptable; only one patient died from complications of myelosuppression. Our results indicate that ABDIC is a potentially curative regimen for a fraction of patients with MOPP-resistant Hodgkin's disease who achieve complete remission with prior MOPP therapy. It also prolongs the survival of patients who do not achieve complete remission with prior MOPP therapy.
 ...
PMID:Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. 619 78

Forty-six previously untreated patients with advanced Hodgkin's disease (3 cases) and non-Hodgkin's lymphoma (Intermediate grade of the Working Formulation) were treated with Adriamycin-based combination chemotherapy at Saitama Cancer Center between January 1977 and December 1982. The median age was 55 years (range, 18-74 years), with 10 patients (22%) 66 years of age or older. The overall complete response rate was 23 of 46 or 50%. The complete response rate of stage III (62.5%) was superior to that (36.4%) of stage IV, but there was no statistical difference between stage III and IV. The complete response in patients with extranodal lymphoma including Waldeyer's ring primary was 9 of 16 (56.2%), while 11 of 27 patients (40.7%) with nodal lymphoma had complete responses. The median survival for all patients was 26 months. The survival curve of complete responders became flat at 41 months and was well sustained with an actuarial survival of 79%. The survival at 5 years was 60% in patients who had stage III and 26% in patients who had stage IV (p greater than 0.05). Congestive heart failure resulting in death occurred in one case given 315mg /m2 of adriamycin and then 90 mg/m2 of mitoxantrone.
 ...
PMID:[Adriamycin-based combination chemotherapy in the treatment of advanced malignant lymphoma. A progress report]. 620 45

The tremendous progress that has been made in the chemotherapy of malignant diseases since the early 1950's has enabled the cure of a significant number of cancers such as chloriocarcinoma, Burkitt's lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma, the acute leukaemias, testicular carcinoma, and many childhood cancers such as rhabdomyosarcoma, Wilm's tumor, Ewing's sarcoma, ovarian cancer, and retinoblastoma. As a result, the mortality from cancers has dropped by 15% for persons under the age of 45 years and even more for those under 30 years of age. Many other metastatic cancers can now be successfully controlled with chemotherapy and, ultimately, more will be added to the growing list of curable cancers. The chemotherapeutic agents responsible for the cures of some cancers include asparaginase, actinomycin D, Adriamycin, bleomycin, cisplatin, cyclophosphamide, cytosine arabinoside, 5-fluorouracil, 6-mercaptopurine, methotrexate, nitrogen mustard, prednisone, procarbazine, and vincristine. The discovery of new effective drugs such as AMSA and anthracenedione promises to improve the success rates obtained with present therapy. Chemotherapy is indicated for every patient who has metastatic cancer, since virtually every patient can receive some palliation from such therapy, while for some patients chemotherapy holds the promise of prolongation of life or even cure.
 ...
PMID:The curability of advanced cancers with chemotherapy. 627 28

Two cases of secondary acute nonlymphocytic leukemia developing after combined chemo-radiotherapy for Hodgkin's disease (HD) are reported. The first case was a 28-year-old woman with PSIIIsA HD, treated with total lymphoid irradiation followed by combination chemotherapy that was almost entirely ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine), who developed acute monoblastic leukemia three years after the diagnosis of Hodgkin's disease. We believe this to be the first reported case of secondary leukemia associated with the combination of radiotherapy and ABVD chemotherapy. The second case was a 37-year-old man with Stage IVB Hodgkin's disease, treated with radiotherapy and MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) who developed acute myeloblastic leukemia five years after the diagnosis of Hodgkin's disease. Both cases showed typical changes of panmyelosis demonstrated by cytochemical and ultrastructural studies. In both cases, bone marrow cells had a dominant clone with a markedly abnormal karyotype. The nature of therapy-related secondary leukemia after Hodgkin's disease and its relationship to current modes of treatment are discussed.
 ...
PMID:Secondary leukemia following treatment of Hodgkin's disease: ultrastructural and cytogenetic data in two cases with a review of the literature. 634 27

Diffuse histiocytic lymphomas (Rappaport) are extranodal lesions frequently formed in the digestive tract. They are clinically different from lymphomas of nodal origin and are no longer considered to arise from histiocytes. They comprise from one-third to one-half of non Hodgkin's lymphomas and chiefly involve the stomach and duodenum. Identification of these tumors and their place in current systems of classification, at present, depends on sophisticated immunologic, histochemical and ultramicroscopic procedures not always suitable for clinical prognosis. Staging laparotomy, useful in Hodgkin's disease, does not always correlate with the prognosis of non Hodgkin's lesions. Radical removal of the affected organ may be curative. Nonresectable lesions may be treated with radiation and chemotherapy. Methotrexate, cyclophosphamide, vincristine, prednisone, nitrogen mustard, Adriamycin, bleomycin and other substances have been used in various combinations to obtain remission of the disease. While results have been favorable, the ideal therapeutic agent has not been found.
 ...
PMID:Diffuse histiocytic lymphomas of the gastrointestinal tract in the adult. 635 9

Within the inhomogeneous group of non Hodgkin's lymphomas, the natural history of lymphomas with favorable histologies, stages III and IV is uncommon; survival can be long, but the relapse rate is high, and finally the ten-year survival rate is poor. In order to improve these results, various proposals have been made. Presently, two main attitudes can be defined. The first one is based on data showing a better survival rate when a complete remission has been obtained; consequently, a very aggressive treatment scheme (for example an association of chemotherapy--including Adriamycin--and total body irradiation) is proposed. The second attitude is based on favorable results obtained by a "deferred treatment", the patients being treated only when the disease is symptomatic. Actually, the review of the literature shows that these two attitudes are complementary rather than antagonistic. For a young adult patient, essentially if histology is more "intermediate" than really "favorable" and if the patient presents with bulky tumoral masses, aggressive treatment must be proposed, because it is the only attitude able to achieve complete remission and therefore able to provide chances of long term survival. For an older patient, essentially with a very favorable histology and without any symptoms such an aggressive therapy appears too risky. "Light" treatments and occasionally "deferred treatment" can be proposed in these cases.
 ...
PMID:[Treatment of non-Hodgkin's lymphomas in adults, stages III and IV with favorable histology : abstention or therapeutic aggressiveness?]. 636 12

Four hematopoietic in vitro cell lines (Hodgkin derived cell lines L428 and L540, Burkitt's lymphoma line BJAB and the lymphoblastic lymphoma line of T-cell type L735) were transplanted into nude mice (NMRI nu/nu) intramuscularly and intracerebrally as well. Tumor bearing mice were treated with intraperitoneal administration of Cyclophosphamide, Adriamycin, Etoposid and Vindesine. Therapy results in both systems were proven by Student's t-test and significances were compared. Resistance and sensitivity of cell lines tested in the i.c.-system were largely in accordance with the i.m.-system. Best results of treatment were achieved with the T-lymphoma line L735 treated with Cyclophosphamide and Etoposid. Cyclophosphamide induced complete remission of i.m. tumors in several cases whereas in the nude mouse brain the L735 cell relapsed and showed a more aggressive growth and diminished drug sensitivity.
 ...
PMID:Experimental chemotherapy of heterotransplanted Hodgkin- and non-Hodgkin-lymphoma cell lines in nude mice. 647 60

A 30-year-old white man with Stage IV B Hodgkin's disease, mixed cellularity type, developed leptomeningeal involvement shortly after relapsing on nitrogen mustard, Oncovin (vincristine), procarbazine, and prednisone (MOPP), and while receiving Adriamycin (doxorubicin), bleomycin, Velban (vinblastine), and dacarbazine (ABVD). Whole brain irradiation and intrathecal methotrexate were successfully incorporated into his treatment program. The patient has now been in complete remission for more than 40 months. A review of this rare complication of Hodgkin's disease is presented.
 ...
PMID:Hodgkin's disease with leptomeningeal involvement. Report of a case with long survival. 654 5

The clinical and pathologic features of 47 cases of malignant lymphoma, diffuse mixed small and large cell (diffuse mixed lymphoma) are described. Diffuse mixed lymphomas contained approximately equal numbers of small and large cells (30-70%) and comprised 6% of all non-Hodgkin's lymphomas. They occurred in middle-aged and elderly patients (median age = 63 years), showed a female predominance, and were clinically advanced at presentation. The majority of patients exhibited prominent extranodal disease, which frequently involved multiple unrelated sites and usually occurred in conjunction with nodal disease. A notable morphologic spectrum of lymphoma was seen within this series, including 20 cases of mixed small cleaved and large cell (with cleaved and noncleaved nuclei), eight cases of mixed small lymphocytic and large cell (transformed prolymphocytes and blast-like cells), and 12 cases of mixed small cell and large cell, "immunoblastic" lymphoma (with plasmacytoid, clear cell or hyperconvoluted features). There was no significant difference in response to treatment and survival between those cases with less than 50% large cells and those with greater than 50% large cells. The poorest treatment response appeared to be in patients with mixed small cell and large cell, "immunoblastic" lymphomas. Patients with diffuse mixed lymphoma appeared to show a favorable response to cyclphosphamide, Adriamycin, vincristine, and prednisone (CHOP) and an unfavorable response to other treatment modalities.
 ...
PMID:Malignant lymphoma, diffuse mixed small and large cell. A clinicopathologic study of 47 cases. 668 99

The effects of chemotherapy and chemoimmunotherapy in previously treated advanced Hodgkin's disease were evaluated in a randomized study of 167 patients by CALGB. Combination chemotherapy consisted of treatment with one of three regimens with further randomization of MER (methanol extraction residue BCG) immunotherapy or no MER during chemotherapy. CVPP (CCNU, vinblastine, procarbazine, prednisone) was compared to a new combination, BAVS (bleomycin, Adriamycin, vincristine, streptozotocin), and to a third regimen consisting of alternating cycles of CVPP and BAVS. At the current analysis there is no significant difference in complete responses among the chemotherapy regimens. MER did not improve complete response frequency and was associated with significantly poorer survival for patients previously treated with chemotherapy. There was also no benefit with MER for patients with at least one pretreatment positive skin test. Because of the documented lack of therapeutic benefit and the morbidity of painful ulcers, MER treatment has been discontinued.
 ...
PMID:MER immunotherapy and combination chemotherapy for advanced, recurrent Hodgkin's disease. Cancer and Leukemia Group B study. 701 26


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>